image dons

I make a donation

ANCHOR

Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients

En cours

Colloquium : Pathologies cardiaques de la femme (15 novembre 2022)
Présentations en ligne !!!

logo étude

objectif

Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients

date de réalisation

2021

nombre de patients

400

nombre de centres participants

36 french sites

type de financement

Public (APHP) and Private (Maquet-Getinge)

Référence

NCT04184635

Assessment of ECMO in acute myocardial infarction with Non-reversible Cardiogenic shock to Halt Organ failure and Reduce mortality (ANCHOR)

Study Description

Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days).
An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of the experimental treatment arm.

  • Experimental : Experimental ECMO + IABP Arm
    VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible.
    An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible).
  • No Intervention: Control Conventional Treatment Arm
    Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.

source clinicaltrials.gov

Autres études

+

AMUNDSEN

En cours


A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....
+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.
+

ACORES-2

En cours


Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.